Breast cancer immunohistochemical features in young women with BRCA1/2 mutations

Breast cancer among young women is a rare pathology. In most studies published so far, this patients group is not being analyzed separately. Particularities of this pathology require an additional examination of the immunohistochemical and molecular-genetic markers of the disease for development of...

Повний опис

Збережено в:
Бібліографічні деталі
Видавець:Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Дата:2009
Автори: Zakhartseva, L.M., Gorovenko, N.G., Podolskaya, S.V., Anikusko, N.F., Lobanova, O.E., Pekur, K.A., Kropelnytskyi, V.A., Shurygina, O.V.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2009
Назва видання:Experimental Oncology
Теми:
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/134403
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Цитувати:Breast cancer immunohistochemical features in young women with BRCA1/2 mutations / L.M. Zakhartseva, N.G. Gorovenko, S.V. Podolskaya, N.F. Anikusko, O.E. Lobanova, K.A. Pekur, V.A. Kropelnytskyi, O.V. Shurygina // Experimental Oncology. — 2009. — Т. 31, № 3. — С. 174-178. — Бібліогр.: 28 назв. — англ.

Репозиторії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id irk-123456789-134403
record_format dspace
spelling irk-123456789-1344032018-06-14T03:04:23Z Breast cancer immunohistochemical features in young women with BRCA1/2 mutations Zakhartseva, L.M. Gorovenko, N.G. Podolskaya, S.V. Anikusko, N.F. Lobanova, O.E. Pekur, K.A. Kropelnytskyi, V.A. Shurygina, O.V. Original contributions Breast cancer among young women is a rare pathology. In most studies published so far, this patients group is not being analyzed separately. Particularities of this pathology require an additional examination of the immunohistochemical and molecular-genetic markers of the disease for development of the effective treatment protocols. The mutations of BRCA1/2 are the important factor impacting to the disease prognosis along the age of the patient. Aim: To compare the expression of prognostically meaningful immunohistochemical markers such as estrogen receptor (ER), progesterone receptor (PR), HER-2, p53, Ki-67, in tumor cells of the female patients with breast cancer aged less than 36 depending on the presence or absence of mutations in BRCA1/2 genes. Methods: Two hundred forty-eight patients aged less than 36 at the time of diagnosis of breast cancer were examined clinically. Expression of ER, PR, HER-2, p53, Ki-67 was determined by indirect immunohistochemical method. Mutations of BRCA1 (185delAG, 5382insC) and BRCA2 (6174delT) genes were screened using multiplex PCR in 99 patients. Results: Mutations of BRCA1/2 genes were found in 9.1% of patients. More aggressive clinical course of the disease was seen in mutations carriers, who had 3-years survival of only 55.6%. They did not demonstrated expression of ER, PR, and HER-2 in 88.9% of the cases. Whereas, patients without BRCA1/2 mutations did not express ER, PR, and HER-2 in only 42.0% of cases. There were no diffe rences between patients with and without mutations in terms of tumor size, presence of metastases in lymph nodes, p53 and Ki-67 expression. Conclusion: Presence of BRCA1/2 genes mutations in young women is associated with more aggressiveness of the breast cancer (their 3-years survival is 25, 5% less) and absence of the ER, PR, HER-2 receptors, which is unfavorable prognostic factor in terms of hormone therapy. These data should be taken into account at chemotherapy planning, especially in patients with early stages of the disease. There were no differences between patients with and without BRCA1/2mutations in terms of tumor size, lymph nodes involvement, tumor histology, and p53 and Ki-67 proteins expression. 2009 Article Breast cancer immunohistochemical features in young women with BRCA1/2 mutations / L.M. Zakhartseva, N.G. Gorovenko, S.V. Podolskaya, N.F. Anikusko, O.E. Lobanova, K.A. Pekur, V.A. Kropelnytskyi, O.V. Shurygina // Experimental Oncology. — 2009. — Т. 31, № 3. — С. 174-178. — Бібліогр.: 28 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/134403 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Original contributions
Original contributions
spellingShingle Original contributions
Original contributions
Zakhartseva, L.M.
Gorovenko, N.G.
Podolskaya, S.V.
Anikusko, N.F.
Lobanova, O.E.
Pekur, K.A.
Kropelnytskyi, V.A.
Shurygina, O.V.
Breast cancer immunohistochemical features in young women with BRCA1/2 mutations
Experimental Oncology
description Breast cancer among young women is a rare pathology. In most studies published so far, this patients group is not being analyzed separately. Particularities of this pathology require an additional examination of the immunohistochemical and molecular-genetic markers of the disease for development of the effective treatment protocols. The mutations of BRCA1/2 are the important factor impacting to the disease prognosis along the age of the patient. Aim: To compare the expression of prognostically meaningful immunohistochemical markers such as estrogen receptor (ER), progesterone receptor (PR), HER-2, p53, Ki-67, in tumor cells of the female patients with breast cancer aged less than 36 depending on the presence or absence of mutations in BRCA1/2 genes. Methods: Two hundred forty-eight patients aged less than 36 at the time of diagnosis of breast cancer were examined clinically. Expression of ER, PR, HER-2, p53, Ki-67 was determined by indirect immunohistochemical method. Mutations of BRCA1 (185delAG, 5382insC) and BRCA2 (6174delT) genes were screened using multiplex PCR in 99 patients. Results: Mutations of BRCA1/2 genes were found in 9.1% of patients. More aggressive clinical course of the disease was seen in mutations carriers, who had 3-years survival of only 55.6%. They did not demonstrated expression of ER, PR, and HER-2 in 88.9% of the cases. Whereas, patients without BRCA1/2 mutations did not express ER, PR, and HER-2 in only 42.0% of cases. There were no diffe rences between patients with and without mutations in terms of tumor size, presence of metastases in lymph nodes, p53 and Ki-67 expression. Conclusion: Presence of BRCA1/2 genes mutations in young women is associated with more aggressiveness of the breast cancer (their 3-years survival is 25, 5% less) and absence of the ER, PR, HER-2 receptors, which is unfavorable prognostic factor in terms of hormone therapy. These data should be taken into account at chemotherapy planning, especially in patients with early stages of the disease. There were no differences between patients with and without BRCA1/2mutations in terms of tumor size, lymph nodes involvement, tumor histology, and p53 and Ki-67 proteins expression.
format Article
author Zakhartseva, L.M.
Gorovenko, N.G.
Podolskaya, S.V.
Anikusko, N.F.
Lobanova, O.E.
Pekur, K.A.
Kropelnytskyi, V.A.
Shurygina, O.V.
author_facet Zakhartseva, L.M.
Gorovenko, N.G.
Podolskaya, S.V.
Anikusko, N.F.
Lobanova, O.E.
Pekur, K.A.
Kropelnytskyi, V.A.
Shurygina, O.V.
author_sort Zakhartseva, L.M.
title Breast cancer immunohistochemical features in young women with BRCA1/2 mutations
title_short Breast cancer immunohistochemical features in young women with BRCA1/2 mutations
title_full Breast cancer immunohistochemical features in young women with BRCA1/2 mutations
title_fullStr Breast cancer immunohistochemical features in young women with BRCA1/2 mutations
title_full_unstemmed Breast cancer immunohistochemical features in young women with BRCA1/2 mutations
title_sort breast cancer immunohistochemical features in young women with brca1/2 mutations
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2009
topic_facet Original contributions
url http://dspace.nbuv.gov.ua/handle/123456789/134403
citation_txt Breast cancer immunohistochemical features in young women with BRCA1/2 mutations / L.M. Zakhartseva, N.G. Gorovenko, S.V. Podolskaya, N.F. Anikusko, O.E. Lobanova, K.A. Pekur, V.A. Kropelnytskyi, O.V. Shurygina // Experimental Oncology. — 2009. — Т. 31, № 3. — С. 174-178. — Бібліогр.: 28 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT zakhartsevalm breastcancerimmunohistochemicalfeaturesinyoungwomenwithbrca12mutations
AT gorovenkong breastcancerimmunohistochemicalfeaturesinyoungwomenwithbrca12mutations
AT podolskayasv breastcancerimmunohistochemicalfeaturesinyoungwomenwithbrca12mutations
AT anikuskonf breastcancerimmunohistochemicalfeaturesinyoungwomenwithbrca12mutations
AT lobanovaoe breastcancerimmunohistochemicalfeaturesinyoungwomenwithbrca12mutations
AT pekurka breastcancerimmunohistochemicalfeaturesinyoungwomenwithbrca12mutations
AT kropelnytskyiva breastcancerimmunohistochemicalfeaturesinyoungwomenwithbrca12mutations
AT shuryginaov breastcancerimmunohistochemicalfeaturesinyoungwomenwithbrca12mutations
first_indexed 2023-10-18T21:07:57Z
last_indexed 2023-10-18T21:07:57Z
_version_ 1796152002660532224